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Introduction: Strong evidence suggests that sudden cardiac death (SCD) is genetically
determined. In our previous study we found that the prevalence of selected, rare coding
variants in 5 long QT genes was signiﬁcantly higher in ventricular ﬁbrillation (VF) survivors
with coronary artery disease (CAD) than in controls. In the present study we performed
mutational analysis of the promoters of 5 LQTS-related myocardial ion channel genes in
the same group of patients and in control populations.
Methods: The promoters of KCNQ1, KCNH2, SCN5A, KCNE1 and KCNE2 genes were analyzed
in 45 CAD individuals – survivors of documented VF. The allelic frequencies were
compared either to data from the 1000 Genomes Project or from a local DNA bank of
patients with coronary artery disease and no malignant arrhythmia (141 individuals).
Results: In 34 (75.5%) of 45 VF survivors 9 different promoter variants were found: 2 in
KCNQ1 gene promoter, 1 in KCNE1 promoter, and 6 in SCN5A promoter. Statistically
signiﬁcant differences were found in the allelic frequencies of both KCNQ1 gene promoter
variants: 1-182C4T (P¼0.008), 1-119G4A (P¼0.007). Nevertheless, these variants did not
segregate with long QT phenotype in a previous study. While the allelic frequency of the
SCN5A gene promoter variant 225-1072T4C signiﬁcantly differed in VF survivors compared
to the 1000 Genomes Project (P¼0.001), this allelic frequency was not different when
compared to the group of local CAD controls.
Conclusions: Our ﬁndings demonstrated that variants of ion channel gene promoters are
common, both in VF survivors and control groups. These results suggest that promoter
variants are geographically-speciﬁc and are not a common cause of SCD.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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There is strong evidence that sudden cardiac death (SCD) is
genetically determined [1–4]. In our previous study we found
that the prevalence of selected, rare coding variants in 5 long
QT genes was signiﬁcantly higher in cases compared to
controls, conﬁrming a mechanistic role for these genes in a
subgroup of patients with coronary artery disease (CAD) who
had suffered ventricular ﬁbrillation (VF) [5].
Ten years after human genome sequencing it has become
clear that coding sequences represent only about 1.5% of
human genome sequence [6]. The remaining portion is either
so called “DNA junk” or, more likely, contains important
regulatory sequences.
In the present study we performed mutational analysis of
the non-coding parts of genes – the promoters – of 5 LQTS-
related myocardial ion channel genes in patients with CAD
who had suffered documented VF at the time of SCD event
and in control population.2. Methods
2.1. Investigated subjects
The group of patients was identical to our previous study [5],
consisting of 45 Caucasian patients (5 females, 40 males) from
the region of south Moravia in the Czech Republic (population
approximately 1.5 million). The primary inclusion criterion
was VF documented at the time of circulatory arrest not
related to acute phase of myocardial infarction (i.e. more than
48 h after index event). Such individuals were identiﬁed from
ICD registry of our department, partially retrospectively
(years 1998–2006), from 2007 new consecutive patients were
included prospectively. Two patients suffered VF while stay-
ing in a hospital for more than 72 h after acute myocardial
infarction. All other individuals suffered circulatory arrest in
the out-of-hospital setting – VF was recorded by emergency
car staff. Patients were successfully resuscitated and then
transferred to our department, either directly or via regional
hospitals. After circulatory stabilization and improvement in
mental status, all patients underwent comprehensive cardi-
ological examination. None of the patients had an acute
myocardial infarction at the time of arrhythmia according
to electrocardiogram (ECG) and serum troponin level analysis.
In all patients coronary artery disease was conﬁrmed by
coronary angiography ﬁndings of signiﬁcant stenoses
(470%) or chronic occlusions. The left ventricle ejectionTable 1 – Clinical characteristics of investigated individuals.
VF survivors (n¼45)
Male/female 40/5
Age 68.679,5
Left ventricle ejection fraction 40712%
History of myocardial infarction 32 (71%)
VF – ventricular ﬁbrillation, CAD – coronary artery disease.fraction (LVEF) was calculated from echocardiography analy-
sis. In three patients, QT interval assessment was not
possible due to left bundle branch block or atrial ﬁbrillation.
None of the other 45 patients showed substantial QT interval
prolongation or Brugada-like ECG.
As a control, we used data from the 1000 Genomes Project,
which sequences the genomes of a large number of people, to
provide a comprehensive resource on human genetic varia-
tion. To date, the database contains data on genetic variation
in 1092 human genomes from various populations [7].
In cases where the data from the 1000 Genomes Project
were not available, another control group was used, consist-
ing of 141 patients with CAD who were hospitalized at our
department owing to an acute coronary event. For all
patients, the diagnosis was conﬁrmed by coronary angiogra-
phy. All patients had depressed LVEF and were alive at least
4 years after the index event and, accordingly, they could be
considered as a CAD group with a low risk of SCD. Clinical
characteristics of both groups of patients are summarized in
Table 1.
Informed consent was obtained from all individuals and
peripheral blood samples were taken for genomic DNA pre-
paration. The study protocol was approved by the Ethical
Committee of the University Hospital Brno and conforms to
the ethical guidelines of the 1975 Declaration of Helsinki.2.2. Genomic DNA samples and polymerase chain
reaction ampliﬁcation
The genomic DNA of all cases was analyzed for mutations in
the promoter sequences of KCNQ1, KCNH2, SCN5A, KCNE1 and
KCNE2 genes. Genomic DNA was extracted from peripheral
blood samples according to a standard protocol using DNA
BloodSpin Kit and the classical method of ethanol progression.
The promoter sequences of KCNQ1, KCNH2 and KCNE1
genes (GenBank accession nos. NG008935.1, NG008916.1,
NG009091.1), were ampliﬁed by multiplex polymerase chain
reaction (PCR). The following primer pairs were designed and
used: 7 primer pairs for KCNQ1 promoter, 6 primer pairs for
KCNH2 promoter and 1 primer pair for KCNE1 promoter. The
PCR ampliﬁcations were performed using HotStarTaq Master
Mix (Qiagen, Inc., Valencia, CA, USA). Each PCR was per
formed in 200-μl thin-walled PCR tubes in a total reaction
volume of 25 μl using Verity Thermal Cycler (Applied Biosys
tem, Foster City, CA, USA).
A total of 12 oligonucleotide primer pairs was designed
and used to amplify the promoter area of the SCN5A gene
(GenBank accession no. AY313163). The core promoterCAD controls (n¼141) p
129/12 0.8181
66.7710.7 0.2885
4279% 0.35238
127 (90%) 0.2718
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pairs 7481–7746 of sequence DQ784804 using the Web Promo
ter Scan Service program, version 1.7. This region was
ampliﬁed using one oligonucleotide primer pair. PCR ampliﬁ
cations were performed using Taq DNA polymerase (Fermen
tas, Inc., Glen Burnie, MD, USA) and HotStarTaq Master Mix
(Qiagen, Inc., Valencia, CA, USA). Each PCR was performed in
200-μl thin-walled PCR tubes in a total reaction volume of
25 μl. Each PCR ampliﬁcation was performed using a Senso
Quest Labcycler (Progen Scientiﬁc, Ltd., Mexborough, UK) and
a Perkin Elmer 2400 machine (Applied Biosystem, Foster City,
CA, USA).2.3. DNA sequencing
DNA sequence analysis was carried out in an ABI 3130
(Applied Biosystem, Foster City, CA, USA) to screen for
KCNQ1, KCNH2, SCN5A, KCNE2 and KCNE1 promoter sequence
variations. Sequencing analyses were performed using for-
ward and reverse primers.
For puriﬁcation of the ampliﬁed samples, the MinElute
PCR Puriﬁcation Kit (Qiagen, Inc., Valencia, CA, USA) was
used. Cycle sequencing was performed using the Big Dye
Terminator Kit (Applied Biosystems, Foster City, CA, USA) and
the DyeEx2.0 Spin Kit (Qiagen, Inc., Valencia, CA, USA) was
used for puriﬁcation of samples after cycle sequencing.
The resulting sequences of the screened KCNQ1, KCNH2,
SCN5A, KCNE2, and KCNE1, gene promoters were aligned with
the wild-type sequences deposited in NCBI (GenBank acces-
sion nos. NG008935.1, NG008916.1, NG009091.1, AY313163,
DQ784804). The numbering was based on Yang et al. [8] and
the allelic frequencies were compared to data from the 1000
Genomes Project, if available [7]. Otherwise the regions
containing sequence variants found in VF survivors were
sequenced in the control group of 141 patients with CAD
without arrhythmias (described above).2.4. Statistics
The distributions of allelic frequencies and their differences
were calculated using χ2 tests. Odds ratio (OR) and 95%
conﬁdence interval (CI) were calculated to estimate the risks
associated with the detected polymorphisms. To calculate
the signiﬁcance of OR, Fisher's exact test was used. The
program package Statistica v. 8.0 (Statsoft Inc., Tulsa, OK,
USA) was used for all statistical analyses.3. Results
In 34 (75.5%) of 45 VF survivors 9 different DNA sequence
variants were found: 2 in KCNQ1 gene promoter, 1 in KCNE1
promoter, and 6 in SCN5A promoter. No variants were
detected in the promoters of KCNH2 and KCNE2 genes.
Variants in more than one gene promoter were present in 6
patients, and multiple variants in single gene promoter were
found in 16 patients.3.1. KCNQ1 gene promoter variants
In KCNQ1 gene promoter variants 1-182C4T and c. 1-119G4A
were found in 15 and 3 patients, respectively. The c. 1-119G4A
polymorphism segregated with the c. 1-182C4T in all 3 cases.
These variants were present in the 1000 Genomes Project data.
3.2. KCNE1 gene promoter variant
A single variant, c. 1-107insG, was found in the KCNE1 gene
promoter in 3 VF survivors. Data on this particular variant
were not available from then 1000 Genomes Project, and its
allelic frequency was tested in the CAD control group.
3.3. SCN5A gene promoter variants
Six promoter variants were found in the SCN5A gene in 22 VF
survivors. More than one SCN5A promoter variant was pre-
sent in 13 VF survivors. The following variants have been
described in the 1000 Genomes Project previously: c. -225-
2038G4T, c. -225-1823C4T, c. -225-834T4C, c. -225-
1744G4C, c. -225-1072T4C. For the c. -225-775T4A variant,
no data were available from the 1000 Genomes Project and,
therefore, its allelic frequency was tested in the CAD
control group.3.4. Statistic results
The allelic frequencies of all promoter variants in the cases
and control groups are summarized in Table 2. Statistically
signiﬁcant differences were found in the allelic frequencies of
both KCNQ1 gene promoter variants: c. 1-182C4T (OR¼2.57,
CI¼1.18–5.57 for the C allele in VF survivors compared to the
CAD group, P¼0.008) and c. 1-119G4A (OR¼7.76, 95%
CI¼1.06–56.77 for the G allele in VF survivors compared to
the control group, P¼0.007). The allelic frequency of SCN5A
gene promoter variant c. 225-1072T4C was signiﬁcantly
different in VF survivors compared to the S1000 Genomes
Project (OR¼7.28, 95% CI¼1.00–53.28 for the T allele in VF
survivors compared to the control group, P¼0.001), but was
not different between the cases and the group of local CAD
controls.4. Discussion
In the present study, we performed a mutation analysis of
promoters of ﬁve cardiac ion channel genes in VF survivors
with CAD to test the hypothesis that polymorphisms in these
regions are more common in VF survivors compared with a
control population. This study was an extension of our
previous study in which we found that the carrier frequency
of rare coding variants of these genes was signiﬁcantly higher
in the VF survivors (8/45, 17.8%) than in CAD controls (3/141,
2.2%, P¼0.001). In the promoter regions of the same genes we
found 9 different DNA sequence variants. The allelic frequen-
cies of three of these variants were signiﬁcantly different
compared to data from 1000 Genomes Project, which was
used as a primary control due its statistical power to detect
Table 2 – Allelic frequencies of promoter variants.
Gene Variant VF survivors (n¼45) 1000 genomes CAD controls (n¼141) P
KCNQ1 c. 1-182C4T C¼0.823 C¼0.643 – 0.008
T¼0.177 T¼0.357
c. 1-119G4A G¼0.967 G¼0.850 – 0.007
A¼0.033 A¼0.150
SCN5A c. -225-2038G4T G¼0.86 G¼0.864 – NS
T¼0.14 T¼0.136
c. -225-1823C4T C¼0.87 C¼0.859 – NS
T¼0.13 T¼0.141
c. -225-1744G4C G¼0.97 G¼0.993 – NS
C¼0.03 C¼0.007
c. -225-1072T4C C¼0 C¼0.142n C¼0.003+ n0.001
T¼1 T¼0.86 T¼0.997 +NS
c. -225-834T4C T¼0.87 T¼0.883 – NS
C¼0.13 C¼0.117
c. -225-775T4A T¼0.98 – T¼1 NS
A¼0.02 A¼0
KCNE1 c. 1-107insG Allele¼0.956 – Allele¼0.933 NS
insG¼0.044 insG¼0.067
VF – ventricular ﬁbrillation, CAD – coronary artery disease, P¼P-value of probability of case-control difference in allelic frequencies, NS – not
signiﬁcant.
n - VF survivors vs. 1000 Genomes,
+ - VF survivors vs. CAD controls
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goal of the 1000 Genomes Project is to identify more than 95%
of single nucleotide polymorphisms at 1% frequency in a
broad set of populations and to date it contains data on
genetic variation from 1092 human genomes in 14 popula-
tions drawn from Europe, East Asia, sub-Saharan Africa and
the Americas [7].
Data on the prevalence of ion channel promoter poly-
morphisms in arrhythmic patients are limited [9]. The variants
we detected in KCNQ1 gene promoter were also present in the
1000 Genome Project dataset and the occurrences of both
polymorphisms in this promoter were signiﬁcantly different in
VF survivors group compared to the 1000 Genomes Project
dataset. Data concerning the possible functional effect of these
polymorphisms are lacking: in our previous work these var-
iants were found also in patients with clinical diagnosis of
long QT syndrome (LQTS) but in no case did the particular
variant segregate with LQTS phenotype [10]. Thus, any possi-
bility of their signiﬁcant functional effect is very limited.
The variant we detected in the KCNE1 gene promoter has
not been described previously [11], and its allelic frequency
did not differ between VF survivors and CAD patients without
malignant arrhythmias.
The SCN5A gene promoter is highly polymorphic, reﬂected
in the fact that in this study we identiﬁed 6 different
polymorphisms in this promoter. With the exception of
c. -225-1072T4C all these variants were the subject of a
study by Yang et al. [8], which found that study only promoter
activity in c. -225-775 T4A variant was signiﬁcantly reduced
in cardiomyocytes. Such variant may modulate sodium-
channel-related physiology in the face of environmental
stressors such as transient myocardial ischemia. Neverthe-
less, allelic frequency of this variant did not differ between VF
survivors and CAD group in our study, indicating that the
potential for a signiﬁcant functional effect is limited.No functional data are available for the variant c. -225-
1072T4C. While the allelic frequencies of this variant were
signiﬁcantly different in VF survivors compared to the 1000
Genomes Project dataset, its allelic frequency in VF survivors
was not different when compared to the group of local CAD
controls. These results indicate that this variant may be a
regionally speciﬁc, and likely to be a non-functional
polymorphism.5. Limitations
There are several limitations to our study, the most impor-
tant of which is the small number of investigated individuals.
Owing to the incidence of SCD events and the capacity of
individual centers to perform routine genetic methods, larger
numbers could only be provided by a multicenter study. Due
to the small number of women included in the present study
it was not possible to perform any sex-related associations.
Allelic frequencies of variants found in VF survivors were
compared with data from the 1000 Genomes Project, which
represents a non-speciﬁc population. In the case of KCNQ
variants, the missing functional studies were substituted by
data from genotype–phenotype analyses in LQTS subjects.6. Conclusion
While variants of ion channel genes promoters are common
both in SCD individuals and control groups, our results
suggest that promoter variants of ion channel genes are not
a common cause of SCD.
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